[
  {
    "ts": null,
    "headline": "Earnings live: Second quarter earnings season off to strong start with Tesla, Google on deck",
    "summary": "Second quarter earnings season kicked off to a strong start. Investors now look ahead to Tesla and Google reporting the first \"Magnificent Seven\" results next week.",
    "url": "https://finnhub.io/api/news?id=9dd115c039f0e58de3525c13dc82f04a6a6151b63c3dce07c052b2ed9d2e95cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752870295,
      "headline": "Earnings live: Second quarter earnings season off to strong start with Tesla, Google on deck",
      "id": 136011109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Second quarter earnings season kicked off to a strong start. Investors now look ahead to Tesla and Google reporting the first \"Magnificent Seven\" results next week.",
      "url": "https://finnhub.io/api/news?id=9dd115c039f0e58de3525c13dc82f04a6a6151b63c3dce07c052b2ed9d2e95cc"
    }
  },
  {
    "ts": null,
    "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
    "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
    "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752851220,
      "headline": "J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?",
      "id": 136007863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.",
      "url": "https://finnhub.io/api/news?id=d2a9086031965b4ec27f20fd36ef39587dbf3fb10ab06cf42c7000555d686142"
    }
  },
  {
    "ts": null,
    "headline": "FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo",
    "summary": "GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.",
    "url": "https://finnhub.io/api/news?id=f9d4168f748aefdc8492dc42407a85fcc281ce8bf6ade7ebc585573445d8811a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752849540,
      "headline": "FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo",
      "id": 136007487,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.",
      "url": "https://finnhub.io/api/news?id=f9d4168f748aefdc8492dc42407a85fcc281ce8bf6ade7ebc585573445d8811a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson price target raised to $167 from $164 at Guggenheim",
    "summary": "Guggenheim raised the firm’s price target on Johnson & Johnson to $167 from $164 and keeps a Neutral rating on the shares after the company delivered a “strong” Q2 and gave an “encouraging outlook” for the company’s growth prospects in the second half. The firm keeps a Neutral rating on J&J shares as it waits for more visibility on the emerging Innovative Medicine pipeline that will need to offset Stelara’s decline, the analyst noted. Published first on TheFly – the ultimate source for real-time",
    "url": "https://finnhub.io/api/news?id=abb41754f645c563d1b5260245f72ec01b3a11bf5b59b3027512b35835ae3a6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752840945,
      "headline": "Johnson & Johnson price target raised to $167 from $164 at Guggenheim",
      "id": 136005440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Guggenheim raised the firm’s price target on Johnson & Johnson to $167 from $164 and keeps a Neutral rating on the shares after the company delivered a “strong” Q2 and gave an “encouraging outlook” for the company’s growth prospects in the second half. The firm keeps a Neutral rating on J&J shares as it waits for more visibility on the emerging Innovative Medicine pipeline that will need to offset Stelara’s decline, the analyst noted. Published first on TheFly – the ultimate source for real-time",
      "url": "https://finnhub.io/api/news?id=abb41754f645c563d1b5260245f72ec01b3a11bf5b59b3027512b35835ae3a6a"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Crypto Clarity, Financial Earnings, JNJ And JOBY",
    "summary": "Crypto legislation back on track, Bitcoin hitting highs. Financial earnings holding ground.",
    "url": "https://finnhub.io/api/news?id=f57bdc1e3315b783f4b721140fcc67f405786cd4e62db71efbf32f1b23a6b71d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752840300,
      "headline": "Wall Street Roundup: Crypto Clarity, Financial Earnings, JNJ And JOBY",
      "id": 136006213,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185432258/image_2185432258.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Crypto legislation back on track, Bitcoin hitting highs. Financial earnings holding ground.",
      "url": "https://finnhub.io/api/news?id=f57bdc1e3315b783f4b721140fcc67f405786cd4e62db71efbf32f1b23a6b71d"
    }
  },
  {
    "ts": null,
    "headline": "Top Dividend Stocks To Consider In July 2025",
    "summary": "The United States market has been flat over the last week but is up 14% over the past year, with earnings forecast to grow by 15% annually. In this environment, dividend stocks can offer a reliable income stream and potential for capital appreciation, making them an attractive consideration for investors seeking stability and growth.",
    "url": "https://finnhub.io/api/news?id=1a2033d511697fa566dacac1f851254aaee965a315c1daa8eeca5bbf61b23570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752838303,
      "headline": "Top Dividend Stocks To Consider In July 2025",
      "id": 136005441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The United States market has been flat over the last week but is up 14% over the past year, with earnings forecast to grow by 15% annually. In this environment, dividend stocks can offer a reliable income stream and potential for capital appreciation, making them an attractive consideration for investors seeking stability and growth.",
      "url": "https://finnhub.io/api/news?id=1a2033d511697fa566dacac1f851254aaee965a315c1daa8eeca5bbf61b23570"
    }
  },
  {
    "ts": null,
    "headline": "Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?",
    "summary": "Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
    "url": "https://finnhub.io/api/news?id=72e93f929995465c7c2449d0b2fc5593eb9024cfc29fe84ef3264327e8a60a9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752837840,
      "headline": "Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?",
      "id": 136005442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
      "url": "https://finnhub.io/api/news?id=72e93f929995465c7c2449d0b2fc5593eb9024cfc29fe84ef3264327e8a60a9d"
    }
  },
  {
    "ts": null,
    "headline": "3M sees smaller tariff hit on 2025 profit amid easing US-China trade tensions",
    "summary": "(Reuters) -3M raised its full-year profit forecast and projected a smaller tariff-related hit to its 2025 earnings on Friday, weeks after the U.S. and China arrived at a trade truce.  As trade tensions show signs of easing, following agreements between the U.S. and other countries including the UK and Vietnam, companies have begun to reevaluate the potential financial fallout.  Pharmaceutical major Johnson & Johnson on Wednesday halved its tariff-related cost projection to $200 million this year.",
    "url": "https://finnhub.io/api/news?id=4d9c1277653453eb0d257b24a56b59e202567d53a721a80528c69652496a0c93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752835081,
      "headline": "3M sees smaller tariff hit on 2025 profit amid easing US-China trade tensions",
      "id": 136005443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Reuters) -3M raised its full-year profit forecast and projected a smaller tariff-related hit to its 2025 earnings on Friday, weeks after the U.S. and China arrived at a trade truce.  As trade tensions show signs of easing, following agreements between the U.S. and other countries including the UK and Vietnam, companies have begun to reevaluate the potential financial fallout.  Pharmaceutical major Johnson & Johnson on Wednesday halved its tariff-related cost projection to $200 million this year.",
      "url": "https://finnhub.io/api/news?id=4d9c1277653453eb0d257b24a56b59e202567d53a721a80528c69652496a0c93"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (NYSE:JNJ) with a price target of $164. The cautious rating comes as the company gets close to releasing its Q2 2025 earnings […]",
    "url": "https://finnhub.io/api/news?id=aaa43274026ef5f06ef337f716d1f170e6bdd74535bc86e9af984c8488f3a2a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752828106,
      "headline": "Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)",
      "id": 136005444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (NYSE:JNJ) with a price target of $164. The cautious rating comes as the company gets close to releasing its Q2 2025 earnings […]",
      "url": "https://finnhub.io/api/news?id=aaa43274026ef5f06ef337f716d1f170e6bdd74535bc86e9af984c8488f3a2a3"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
    "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
    "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752820500,
      "headline": "The Davenport Balanced Fund Q2 2025 Commentary",
      "id": 136000852,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2010464790/image_2010464790.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Davenport blends dividend discipline, bond yield upside, and contrarian equity picks in DBALX. See how balanced investing still finds value in 2025.",
      "url": "https://finnhub.io/api/news?id=4bdb422e2c4856f5d9f3007eff0a2fbd75d7735fa999ca6fde264ed6f71dd73f"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "summary": "The Davenport Value & Income Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752819300,
      "headline": "The Davenport Value & Income Fund Q2 2025 Commentary",
      "id": 136000824,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8fe250ebddd0c5cd485b556d16dd47deb781d90003a77552d4b3581b3cadd026"
    }
  },
  {
    "ts": null,
    "headline": "Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth",
    "summary": "The company’s custom implants compete with devices from Medtronic, Johnson & Johnson and Globus Medical.",
    "url": "https://finnhub.io/api/news?id=9a41f11cb24a3937ec39c0bf5581b3dd22553f4d6e666b8ffdc79564fa38b585",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752815493,
      "headline": "Carlsmed seeks up to $103M IPO haul to fuel spine surgery growth",
      "id": 136005445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company’s custom implants compete with devices from Medtronic, Johnson & Johnson and Globus Medical.",
      "url": "https://finnhub.io/api/news?id=9a41f11cb24a3937ec39c0bf5581b3dd22553f4d6e666b8ffdc79564fa38b585"
    }
  }
]